US7547719 — 3â²-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2â²-hydroxy-[1,1â²-piphenyl]-acid bis-(monoethanolamine)
Method of Use · Assigned to SmithKline Beecham Corp · Expires 2025-07-13 · 1y expired
What this patent protects
This patent protects the use of the bis-(monoethanolamine) salt of a specific thrombopoietin mimetic compound.
USPTO Abstract
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3â²-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2â²-hydroxy-[1,1â²-biphenyl]-3-carboxylic acid.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1575 |
— | eltrombopag-olamine |
U-1575 |
— | eltrombopag-olamine |
U-2451 |
— | eltrombopag-olamine |
U-1575 |
— | eltrombopag-olamine |
U-2452 |
— | eltrombopag-olamine |
U-2451 |
— | eltrombopag-olamine |
U-2451 |
— | eltrombopag-olamine |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.